AtriCure Inc
NASDAQ:ATRC
Net Margin
AtriCure Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
AtriCure Inc
NASDAQ:ATRC
|
1.8B USD |
-8%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
224B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
179.3B USD |
29%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
157.5B USD |
14%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
153.7B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
118.1B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
55.5B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
52.2B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.6B USD |
73%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.5B USD |
23%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
40.8B USD |
26%
|
AtriCure Inc
Glance View
Nestled in the heart of the highly competitive medical device industry, AtriCure Inc. has carved a significant niche for itself by focusing on the surgical treatment of atrial fibrillation, a common and potentially serious heart rhythm disorder. Founded in 2000 and headquartered in Mason, Ohio, AtriCure designs, manufactures, and sells an array of surgical devices aimed at improving treatment outcomes for this condition. The company’s innovative technology targets the complex network of electrical signals in the heart to restore regular rhythm and mitigate the risk of stroke—a common consequence of untreated atrial fibrillation. By providing surgeons with minimally invasive tools and advanced cryoablation and radiofrequency therapy systems, AtriCure not only addresses surgical efficiency but also enhances patient recovery times, distinguishing itself from its competitors. AtriCure derives its revenue from the sale of these sophisticated products directly to hospitals and surgical centers both in the United States and internationally. Key components of its portfolio include the Synergy Ablation System, which is acclaimed for its precision in creating lesions that block erratic electrical pathways, and AtriClip, a line of devices designed to occlude the left atrial appendage, thereby reducing stroke risk. As healthcare providers increasingly recognize the benefits of surgical intervention for atrial fibrillation over alternative treatments, AtriCure's financial health is buoyed by the rising adoption of its products. The company's strategic focus on expanding its product pipeline and enhancing its global sales footprint underscores its commitment to continuous growth and innovation in cardiac care.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on AtriCure Inc's most recent financial statements, the company has Net Margin of -8%.
You don't have any saved screeners yet